The FDA’s recent approval of Esketamine (Spravato by Janssen Pharmaceuticals) has been met with much excitement (and some controversy) for it’s potential to help people with treatment-resistant depression. Despite it being a potentially life-threatening condition treatment-resistant depression medication options are limited. 12-20% of people diagnosed with major depression don’t respond to conventional antidepressant treatment.